Clari ACE
AI diagnostic solution for medical imaging analysis
Software · On PremiseCompany source
Company profile
About ClariPI
ClariPi Inc. was founded in February 2015 to provide innovative solutions for unmet needs in medical imaging through the convergence of intelligent big data computing and medical imaging technologies. The company specializes in AI-based medical imaging diagnostic solutions, bringing together experts in engineering and medicine to develop products that help medical imaging professionals make confident decisions with clearer information and convenient decision guidance. The company's flagship product, ClariCT.AI, is a vendor-neutral CT denoising solution based on deep learning technology. The solution's Deep-learned Clarity Engine removes CT noise and transforms existing CT scanners into AI-empowered systems using only the DICOM standard. ClariCT.AI provides multiple deep learning models pretrained with millions of images for different organs at varying noise levels from most existing scanner models, distinguishing anatomical structures from thousands of different noise patterns to deliver noise-clean, high-quality images. The technology enables ultra-low-dose CT scans to achieve image quality comparable to high-dose CT images, removing strong noise and artifacts without distortion or plastic appearance. Beyond CT denoising, ClariPi has developed a comprehensive suite of AI-powered diagnostic solutions including Clari Pulmo for emphysema, Clari SIGMAM for breast density assessment, Clari Adipo for abdominal metabolic syndrome, Clari Osteo for bone health, Clari ACE, and Clari Sarco for muscle assessment. These solutions leverage AI image processing and big data technology to address various clinical needs across radiology and medical imaging. The company serves radiologists, healthcare institutions, and medical imaging centers globally, with particular adoption in Europe and Asia.
Company description ClariPI official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at ClariPI?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Abdominal metabolic syndrome
- Breast density assessment
- Emphysema
- General CT imaging
- Liver fat
- Lung nodules
- Osteoporosis
- Respiratory diseases
- Sarcopenia
Who it serves
- Academic Medical Centers
- Health Systems
- Hospitals
- Radiology Centers
Deployment & integration
On Premise deployment with recorded integration context.
Recorded integration context: DICOM standard, Vendor-neutral CT scanner compatibility.
Geographic context
MarketsAsia · Europe · Germany · South Korea · United States
Company sourceOfficial website
Company milestones
Platform expansion
Multiple FDA, CE, and MFDS regulatory clearances for product portfolio. Expansion of product line beyond CT denoising to include organ-specific diagnostic solutions. Establishment of US office in Michigan.
Partnerships
Recorded partners
- Chung-Ang University Hospital
- Johannes Gutenberg University Mainz
- Seoul National University
- University Hospital Tuebingen
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Clari Adipo
AI solution for adipose tissue analysis and liver fat assessment
Software · On PremiseCompany source
Clari Osteo
AI-based bone density and osteoporosis assessment solution
Software · On PremiseCompany source
Clari Pulmo
AI-powered pulmonary imaging diagnostic solution
Software · On PremiseCompany source
Clari Sarco
AI solution for sarcopenia and muscle mass assessment
Software · On PremiseCompany source
Clari SIGMAM
AI diagnostic solution for abdominal metabolic syndrome assessment
Software · On PremiseCompany source
ClariCT.AI
Vendor-neutral CT denoising solution using Deep Learning for ultra-low-dose imaging
Software · On PremiseCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Automatic hepatic steatosis quantification using low-dose CT with deep learning-based noise reduction and CT fat fraction analysis software.The British journal of radiology · Jun 1, 2026
Computed Tomography-Based Artificial Intelligence Analysis of Myosteatosis and Its Effect on Survival in Fournier Gangrene.The world journal of men's health · May 22, 2026
Deep Learning-Based Augmented Contrast-Enhancement and Denoising for Reduced-Iodine and Low-Radiation 70-kVp Cerebral CT Angiography: A Prospective Study.Korean journal of radiology · May 1, 2026
Muscle Loss Driven by Extracellular Signal-Regulated Kinase Suppression via β-Adrenergic Activation in High-Normal Catecholamine Status.Endocrinology and metabolism (Seoul, Korea) · Apr 1, 2026
Deep Learning Denoising Algorithm for Improved Assessment of Coronary Arteries in Transcatheter Aortic Valve Implantation CT Imaging.Academic radiology · Feb 1, 2026
Performance of fully automated deep-learning-based coronary artery calcium scoring in ECG-gated calcium CT and non-gated low-dose chest CT.European radiology · Nov 1, 2025
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
ClariPulmoK203783 · 510k · Apr 6, 2022
ClariSIGMAMK203785 · 510k · Sep 10, 2021
ClariCT.AIK212074 · 510k · Jul 27, 2021
ClariCT.AIK183460 · 510k · Jun 13, 2019
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Radiation dose reduction of 40-75%
Ultra-low-dose CT imaging while maintaining diagnostic quality
Image quality comparable to high-dose CT
When using ultra-low-dose protocols with ClariCT.AI
Improved nodule detection
In lung CT scans at reduced radiation doses
University Hospital Tuebingen
Significantly improved CT image quality at much lower radiation doses across various clinical applications
Significantly improved image quality at much lower radiation dose
Leaders Internal Medicine Radiology
Ultra-low-dose lung CT for respiratory disease diagnosis and nodule detection
40-50% reduction in general low-dose lung CT dose with improved image quality and better nodule detection
The Medical Center of Johannes Gutenberg University Mainz
Meeting low-dose regulations while maintaining diagnostic image quality for routine CT scans
CT dose reduced to less than 1/4 while maintaining or improving image quality compared to normal dose
Chung-Ang University Hospital
Vendor-neutral automatic image denoising compatible with any CT equipment brand for radiation dose reduction
Optimal images with small dose across wide range of body applications
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Jong Hyo Kim
CEO
Hyun Sook Park
President
06 · Company updates
Updates from ClariPI
Recent articles published on ClariPI's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.